Kyle E Rodenbach1, Michael F Schneider2, Susan L Furth3, Marva M Moxey-Mims4, Mark M Mitsnefes5, Donald J Weaver6, Bradley A Warady7, George J Schwartz8. 1. University of Rochester Medical Center, Rochester, NY. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Children's Hospital of Philadelphia, Philadelphia, PA. 4. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 5. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 6. Levine Children's Hospital, Charlotte, NC. 7. Children's Mercy Hospital, Kansas City, MO. 8. University of Rochester Medical Center, Rochester, NY. Electronic address: george_schwartz@urmc.rochester.edu.
Abstract
BACKGROUND: Hyperuricemia is associated with essential hypertension in children. No previous studies have evaluated the effect of hyperuricemia on progression of chronic kidney disease (CKD) in children. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: Children and adolescents (n=678 cross-sectional; n=627 longitudinal) with a median age of 12.3 (IQR, 8.6-15.6) years enrolled at 52 North American sites of the CKiD (CKD in Children) Study. PREDICTOR: Serum uric acid level (<5.5, 5.5-7.5, and >7.5mg/dL). OUTCOMES: Composite end point of either >30% decline in glomerular filtration rate (GFR) or initiation of renal replacement therapy. MEASUREMENTS: Age, sex, race, blood pressure status, GFR, CKD cause, urine protein-creatinine ratio (<0.5, 0.5-<2.0, and ≥2.0mg/mg), age- and sex-specific body mass index > 95th percentile, use of diuretics, and serum uric acid level. RESULTS: Older age, male sex, lower GFR, and body mass index > 95th percentile were associated with higher uric acid levels. 162, 294, and 171 participants had initial uric acid levels < 5.5, 5.5 to 7.5, or >7.5 mg/dL, respectively. We observed 225 instances of the composite end point over 5 years. In a multivariable parametric time-to-event analysis, compared with participants with initial uric acid levels < 5.5mg/dL, those with uric acid levels of 5.5 to 7.5 or >7.5mg/dL had 17% shorter (relative time, 0.83; 95% CI, 0.62-1.11) or 38% shorter (relative time, 0.62; 95% CI, 0.45-0.85) times to event, respectively. Hypertension, lower GFR, glomerular CKD cause, and elevated urine protein-creatinine ratio were also associated with faster times to the composite end point. LIMITATIONS: The study lacked sufficient data to examine how use of specific medications might influence serum uric acid levels and CKD progression. CONCLUSIONS: Hyperuricemia is a previously undescribed independent risk factor for faster progression of CKD in children and adolescents. It is possible that treatment of children and adolescents with CKD with urate-lowering therapy could slow disease progression.
BACKGROUND:Hyperuricemia is associated with essential hypertension in children. No previous studies have evaluated the effect of hyperuricemia on progression of chronic kidney disease (CKD) in children. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: Children and adolescents (n=678 cross-sectional; n=627 longitudinal) with a median age of 12.3 (IQR, 8.6-15.6) years enrolled at 52 North American sites of the CKiD (CKD in Children) Study. PREDICTOR: Serum uric acid level (<5.5, 5.5-7.5, and >7.5mg/dL). OUTCOMES: Composite end point of either >30% decline in glomerular filtration rate (GFR) or initiation of renal replacement therapy. MEASUREMENTS: Age, sex, race, blood pressure status, GFR, CKD cause, urine protein-creatinine ratio (<0.5, 0.5-<2.0, and ≥2.0mg/mg), age- and sex-specific body mass index > 95th percentile, use of diuretics, and serum uric acid level. RESULTS: Older age, male sex, lower GFR, and body mass index > 95th percentile were associated with higher uric acid levels. 162, 294, and 171 participants had initial uric acid levels < 5.5, 5.5 to 7.5, or >7.5 mg/dL, respectively. We observed 225 instances of the composite end point over 5 years. In a multivariable parametric time-to-event analysis, compared with participants with initial uric acid levels < 5.5mg/dL, those with uric acid levels of 5.5 to 7.5 or >7.5mg/dL had 17% shorter (relative time, 0.83; 95% CI, 0.62-1.11) or 38% shorter (relative time, 0.62; 95% CI, 0.45-0.85) times to event, respectively. Hypertension, lower GFR, glomerular CKD cause, and elevated urine protein-creatinine ratio were also associated with faster times to the composite end point. LIMITATIONS: The study lacked sufficient data to examine how use of specific medications might influence serum uric acid levels and CKD progression. CONCLUSIONS:Hyperuricemia is a previously undescribed independent risk factor for faster progression of CKD in children and adolescents. It is possible that treatment of children and adolescents with CKD with urate-lowering therapy could slow disease progression.
Authors: David A Colantonio; Lianna Kyriakopoulou; Man Khun Chan; Caitlin H Daly; Davor Brinc; Allison A Venner; Maria D Pasic; David Armbruster; Khosrow Adeli Journal: Clin Chem Date: 2012-02-27 Impact factor: 8.327
Authors: Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth Journal: Am J Kidney Dis Date: 2015-03-19 Impact factor: 8.860
Authors: Arnold B Alper; Wei Chen; Lillian Yau; Sathanur R Srinivasan; Gerald S Berenson; L Lee Hamm Journal: Hypertension Date: 2004-11-29 Impact factor: 10.190
Authors: Cristin D W Kaspar; Isidora Beach; Jennifer Newlin; India Sisler; Daniel Feig; Wally Smith Journal: Pediatr Nephrol Date: 2020-01-20 Impact factor: 3.714